STAT3 as a central mediator of neoplastic cellular transformation

Cancer Letters

Volumn 251, Issue 2, 2007, Pages 199-210

  Frank, David A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Gene expression; Molecular oncology; Protein phosphorylation; Signal transduction; Transcription factors

Indexed keywords

STAT3 PROTEIN;

ANGIOGENESIS; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSFORMATION; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 34247600538     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.10.017     Document Type: Review

References (72)

1. Nowell P.C., and Hungerford D.A. A minute chromosome in human chronic granulocytic leukemia. Science 132 (1960) 1497-1499
2. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
3. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2 (1996) 561-566
4. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
5. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
6. Grignani F., De M.S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Grignani F., Lazar M.A., Minucci S., and Pelicci P.G. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia. Nature 391 (1998) 815-818
7. Warrell Jr. R.P., Frankel S.R., Miller W.J.J., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreef M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M.S., and Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with triretinoin (all-trans retinoic acid). N. Engl. J. Med. 324 (1991) 1385-1391
8. Darnell Jr. J.E. STATs and gene regulation. Science 277 (1997) 1630-1635
9. Nelson E.A., Walker S.R., Alvarez J.A., and Frank D.A. Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification. J. Biol. Chem. 279 (2004) 54724-54730
10. Chung J., Uchida E., Grammer T.C., and Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol. 17 (1997) 6508-6516
11. Wen Z., Zhong Z., and Darnell Jr. J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995) 241-250
12. Zhang X., Blenis J., Li H.-C., Schindler C., and Chen-Kiang S. Requirement of serine phosphorylation for formation of Stat-promoter complexes. Science 267 (1995) 1990-1994
13. Morita Y., Naka T., Kawazoe Y., Fujimoto M., Narazaki M., Nakagawa R., Fukuyama H., Nagata S., and Kishimoto T. Signals transducers and activators of transcription (STAT)-induced STAT inhibitor-1 (SSI-1)/suppressor of cytokine signaling-1 (SOCS-1) suppresses tumor necrosis factor alpha-induced cell death in fibroblasts. Proc. Natl. Acad. Sci. USA 97 (2000) 5405-5410
14. Kim T.K., and Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 273 (1996) 1717-1719
15. ten Hoeve J., de Jesus Ibarra-Sanchez M., Fu Y., Zhu W., Tremblay M., David M., and Shuai K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol. Cell. Biol. 22 (2002) 5662-5668
16. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., Harris C.C., and Herman J.G. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28 (2001) 29-35
17. Galm O., Yoshikawa H., Esteller M., Osieka R., and Herman J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101 (2003) 2784-2788
18. Chim C.S., Fung T.K., Cheung W.C., Liang R., and Kwong Y.L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103 (2004) 4630-4635
19. Lee T.L., Yeh J., Van Waes C., and Chen Z. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and EGF receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol. Cancer Ther. 5 (2006) 8-19
20. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 295-303
21. Liddle F.J., Alvarez J.A., Poli V., and Frank D.A. Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants. Biochemistry 45 (2006) 5599-5605
22. Raz R., Durbin J.E., and Levy D.E. Acute phase response factor and additional members of the interferon-stimulated gene factor 3 family integrate diverse signals from cytokines, interferons, and growth factors. J. Biol. Chem. 269 (1994) 24391-24395
23. Alvarez J.V., and Frank D.A. Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis. Cancer Biol. Ther. 3 (2004) 1045-1050
24. Alvarez J.V., Febbo P.G., Ramaswamy S., Loda M., Richardson A., and Frank D.A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 65 (2005) 5054-5062
25. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
26. Masuda M., Suzui M., Yasumatu R., Nakashima T., Kuratomi Y., Azuma K., Tomita K., Komiyama S., and Weinstein I.B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62 (2002) 3351-3355
27. Kijima T., Niwa H., Steinman R.A., Drenning S.D., Gooding W.E., Wentzel A.L., Xi S., and Grandis J.R. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Diff. 13 (2002) 355-362
28. Ishii Y., Pirkmaier A., Alvarez J.V., Frank D.A., Keselman I., Logothetis D., Mandeli J., O'Connell M.J., Waxman S., and Germain D. Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J. Natl. Cancer Inst. 98 (2006) 1238-1247
29. Isomoto H., Kobayashi S., Werneburg N.W., Bronk S.F., Guicciardi M.E., Frank D.A., and Gores G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression by a JAK/STAT3 pathway in cholangiocarcinoma cells. Hepatology 42 (2005) 1329-13338
30. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., Kawashima T., Nanakin A., Sawabu T., Uenoyama Y., Sekikawa A., Kawada M., Suzuki K., Kayahara T., Fukui H., Sawada M., and Chiba T. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cacer cells. Oncogene 23 (2004) 4921-4929
31. Aoki Y., Feldman G.M., and Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003) 1535-1542
32. Xie T.X., Wei D., Liu M., Gao A.C., Ali-Osman F., Sawaya R., and Huang S. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 23 (2004) 3550-3560
33. Itoh M., Murata T., Suzuki T., Shindoh M., KNakajima K., Imai K., and Yoshida K. Requirement of STAT3 activaiton for maximal collagenase-1 (MMP-1) induction by epidermal growth factor and malignant characteristics in T24 bladder cancer cells. Oncogene 25 (2006) 1195-1204
34. Xie T.-X., Huang F.-J., Aldape K.D., Kang S.-H., Liu M., Gershenwald J.E., Xie K., Sawaya R., and Huang S. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res. 66 (2006) 3188-3196
35. Wang H.Y., Woetmann A., Raghunath P.N., Odum N., and Wasik M.A. STAT3 induces transcription of the DNA methyl transferase 1 gene (DNMT1) in malignant T lymphocytes. Blood 108 (2006) 1058-1064
36. Frank D.A. STAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat. Res. 115 (2003) 267-291
37. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H., and Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988) 83-85
38. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., and Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
39. Li L., and Shaw P.E. Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines. J. Biol. Chem. 277 (2002) 17397-17405
40. DeArmond D., Brattain M.G., Jessup J.M., Kreisberg J., Malik S., Zhao S., and Freeman J.W. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. Oncogene 22 (2003) 7781-7795
41. Rawat R., Rainey G.J., Thompson C.D., Frazier-Jessen M.R., Brown R.T., and Nordan R.P. Constitutive activation of STAT3 is associated with the acquisition of an interleukin 6-independent phenotype by murine plasmacytomas and hybridomas. Blood 96 (2000) 3514-3521
42. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., and Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin. Cancer Res. 9 (2003) 370-376
43. Yoshida T., Hanada T., Tokuhisa T., Kosai K.-i., Sata M., Kohara M., and Yoshimura A. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J. Exp. Med. 196 (2002) 641-653
44. Alvarez J.V., Greulich H., Sellers W.R., Meyerson M., and Frank D.A. STAT3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the EGF receptor. Cancer Res. 66 (2006) 3162-3168
45. Frank D.A., Mahajan S., and Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest. 100 (1997) 3140-3148
46. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., Peng Z., Huang S., Xiong H.Q., Abbruzzese J.L., and Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
47. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., Baumann H., and Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99 (2002) 252-257
48. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., Muro-Cacho C.A., Livingston S., Karras J., Pow-Sang J., and Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002) 6659-6666
49. Chiarle R., Simmons W.J., Cai H., Dhall G., Zamo A., Raz R., Karras J.G., Levy D.E., and Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat. Med. 11 (2005) 623-629
50. Takeda K., Noguchi K., Shi W., Tanaka T., Matsumoto M., Yoshida N., Kishimoto T., and Akira S. Targeted disruption of the mouse STAT3 gene leads to early embryonic lethality. Proc. Natl. Acad. Sci. 94 (1997) 3801-3804
51. Schlessinger K., and Levy D.E. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res. 65 (2005) 5828-5834
52. Takeda K., and Akira S. Multi-functional roles of Stat3 revealed by conditional gene targeting. Arch. Immunol. Ther. Exp. (Warsz) 49 (2001) 279-283
53. Sano S., Itami S., Takeda K., Tarutani M., Yamaguchi Y., Miura H., Yoshikawa K., Akira S., and Takeda J. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18 (1999) 4657-4668
54. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., and DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 114 (2004) 720-728
55. Ling X., and Arlinghaus R.B. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res. 65 (2005) 2532-2536
56. Weinstein I.B. Addiction to oncogenes - the Achilles heal of cancer. Science 297 (2002) 63-64
57. Turkson J., Ryan D., Kim J.S., Zhang Y., Chen Z., Haura E., Laudano A., Sebti S., Hamilton A.D., and Jove R. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276 (2001) 45443-45455
58. Turkson J., Kim J.S., Zhang S., Yuan J., Huang M., Glenn M., Haura E., Sebti S., Hamilton A.D., and Jove R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 3 (2004) 261-269
59. Song H., Wang R., Wang S., and Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. USA 102 (2005) 4700-4705
60. Battle T.E., and Frank D.A. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to bryostatin 1. Blood 102 (2003) 3016-3024
61. Barton B.E., Murphy T.F., Shu P., Huang H.F., Meyenhofen M., and Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol. Cancer Res. 3 (2004) 1183-1191
62. Jing N., Xiong I.Y.W., Sha W., Jing L., and Tweardy D.J. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppress growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 64 (2004) 6603-6609
63. Real P.J., Sierra A., de Juan A., Segovia J.C., Lopez-Vega J.M., and Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 21 (2002) 7611-7618
64. Alas S., and Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin. Cancer Res. 9 (2003) 316-326
65. Turkson J., Zhang S., Mora L.B., Burns A., Sebti S., and Jove R. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J. Biol. Chem. 280 (2005) 32979-32988
66. Turkson J., Zhang S., Palmer J., Kay H., Stanko J., Mora L.B., Sebti S., Yu H., and Jove R. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol. Cancer Ther. 3 (2004) 1533-1542
67. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., and Sebti S.M. Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/Signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63 (2003) 1270-1279
68. Sun J., Blaskovich M.A., Jove R., Livingston S.K., Coppola D., and Sebti S. Curcurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24 (2005) 3236-3245
69. Lee Y.K., Isham C.R., Kaufman S.H., and Bible K.C. Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combins with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy. Mol. Cancer Ther. 5 (2006) 138-148
70. Li L., Hooi D., Chhabra S.R., Pritchard D., and Shaw P.E. Bacterial N-acylhomoserine lactone-induced apoptosis in breast carcinoma cells correlated with down-modulation of STAT3. Oncogene 23 (2004) 4894-4902
71. Liby K., Voong N., Williams C.R., Risingsong R., Royce D.B., Honda T., Gribble G.W., Sporn M.B., and Letterio J.J. The synthetic triterpenoid CDDO-imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin. Cancer Res. 12 (2006) 4288-4293
72. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., and Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11 (2005) 1314-1321